Ellence Research Fund Names 11 Grant Recipients

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 3
Volume 10
Issue 3

PEAPACK, NJ- Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals.

PEAPACK, NJ— Pharmacia Oncology has announced the 11 recipients of its first $1 million Ellence Research Fund, aimed at promoting research to advance the use of anthracyclines in various cancer settings. The recipients were chosen by a scientific advisory board composed of leading oncologists. The company has created a second $1 million Ellence Research Fund and is currently accepting research proposals. (For more information, contact Lynn Stoltzfus at lynn.stoltzfus@am.pnu.com.)

The 2001 winners are: Glenn Bubley, MD, Beth Israel Deaconess Medical Center, Boston; Joan Bull, MD, University of Texas-Houston Medical School; Luke Dreisbach, MD, Arizona Cancer Center, Tucson; Phil Gold, MD, Swedish Medical Center Tumor Institute, Seattle; Daniel Haller, MD, University of Pennsylvania Cancer Center, Philadelphia; and Jon Herrington, PhD, Scott and White Memorial Hospital, Temple, Texas.

Also, Peter Kennedy, MD, Kenmar Research Institute, Los Angeles; Pam Khosla, MD, Rush-Presbyterian-St. Luke’s Medical Center, Chicago; Silvana Martino, DO, John Wayne Cancer Institute, Santa Monica, California; Lajos Pusztai, PhD, M.D. Anderson; and Christopher Ryan, MD, University of Chicago.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content